If you have been reading about synaptic plasticity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
=== Differential diagnosis === Juvenile idiopathic arthritis may closely resemble the clinical presentation of some osteochondrodysplasias or genetic skeletal dysplsias. In that, both conditions can present with swollen, stiff and deformed joints. Type II collagen disorders are caused by variants in the COL2A1 gene. Type II collagen disorders can result in mild disease or severe which can cause death within weeks of birth. Infants with the severe form of the disease would be born with clear indications of the disease, such as disproportionate short stature, skeletal dysplasia, distinctive eye abnormalities, cleft palate, and others. However, infants with mild disease may only experience arthritis at birth, but may progress to more severe disease later in life. Early diagnosis can be challenging. Furthermore, type II collagenopathies have significant phenotypic overlap with conditions such as MPS. Guidelines are available to ensure healthcare professional are aware of the conditions and the symptoms of disease to support efficient diagnosis.
== List of Russian drugs == Aceclidine (Glaucostat, Glaunorm, Glaudin) – parasympathomimetic miotic Acetomepregenol (ACM; mepregenol diacetate; Diamol) – progestin Adapromine (1-(1′-adamantyl)propylamine; Etandan) – adamantane, antiviral, psychostimulant, antidepressant Alafen (alaphen, alafena; amphetamine–β-alanine) – amphetamine derivative, antiserotonergic Arabinopyranosyl-N-methyl-N-nitrosourea (Aranose, Aranoza) – antineoplastic agent Bemethyl (bemitil) – actoprotector Bromantane (Ladasten) – psychostimulant, antidepressant, anxiolytic, adaptogen/actoprotector, immunostimulant Butagest – progestin Carubicin – anthracycline antineoplastic agent Cepentil (tsepentil, N-cyclopentyllysergamide, LCyP) – lysergamide antiserotonergic Chlodantane (chlodantan; ADK-910) – adamantane, adaptogen/actoprotector, immunostimulant Chloracyzine – tricyclic antidepressant, phenothiazine, coronary vasodilator, antianginal Cortifen (cortiphen, kortifen, fencoron) – glucocorticoid, antineoplastic agent Corvalol (corvalolum, Korvalol) – tranquilizer, based on phenobarbital and containing various natural ingredients. In Russia it is sold without prescription, despite the fact that ordinary phenobarbital tablets are sold strictly by doctor's prescription.
=== Labeling === For US food and dietary supplement labeling purposes, the amount in a serving is expressed as a percent of Daily Value. Since 27 May 2016, the Daily Value has been 1.2 mg, in line with the RDA.
== Development from 'Peptide 3' == 'Peptide 3' is a 12-amino acid linear peptide corresponding to amino acids 51 to 62 of mature human chemokine CCL2. It is formed from L-amino acids with the sequence NH2-Glu-Ile-Cys-Ala-Asp-Pro-Lys-Gln-Lys-Trp-Val-Gln-OH (or in single letter code NH2-EICADPKQKWVQ-OH). 'Peptide 3' was found to be a Broad-Spectrum Chemokine Inhibitor inhibiting chemotaxis of human myelomonocytic cell line THP-1 monocytes and human neutrophils induced by a range of chemokines including CCL2, CCL3, CXCL8 and CXCL12 with roughly equal potency of 10μM, but not migration induced by other non-chemokine chemoattractants such as n-formyl-Met-Leu-Phe (fMLP) or TGF-β. Biotinylated 'Peptide 3' was found to bind to THP-1 cells with a disassociation constant of roughly 10μM. This suggested that 'Peptide 3' functions as a chemokine receptor antagonist. This mechanism was later proved to not be in action.
Sources: en.wikipedia.org
== Dynamic structures and modifications == As in the broader field of DNA nanotechnology, DNA origami may be made dynamic in nature through the use of a variety of methods. The three primary methods of creating a dynamic DNA origami machine are toehold mediated strand displacement, enzymatic reactions, and base stacking. While these methods are most commonly used, additional methods for creating dynamic DNA origami machines exist, such as designing a directional component and using brownian motion to drive rotational movement of structures or leveraging less commonly used DNA self-assembly phenomena like G-quadruplexes or i-motifs which can be pH sensitive.
== Use == L-RNA aptamers have been obtained for the chemokines CCL2 and CXCL12, the complement components C5a and ghrelin. They are currently in preclinical or clinical development. Proof-of-concept for an anti-CCL2/MCP-1 L-RNA aptamers has recently been demonstrated in diabetic nephropathy patients. They can also be used as diagnostic agents.
Advisors are large larvae-like aliens which are virtually featureless, with no visible eyes, ears or limbs, although they do possess an eye-like mechanical device attached to the left side of their heads, and detachable mechanical arms. Their faces are covered by a respirator, which is able to lift to reveal a mouth-like orifice from which they can extend a long and flexible proboscis. With this, they can examine objects, or attack and kill other creatures. Advisors appear to be feeding upon their victim during their attacks. It is implied that Advisors are the Combine's ruling class, with Breen answering directly to them. Although Advisors are usually seen in protective pods guarded by Combine soldiers, they also possess psychokinesis with which they are able to float through the air and immobilize other creatures so that their proboscis can examine victims without interference. Their appearance was based on the Guild Navigators from the 1984 film Dune.
=== Kinetic and equilibrium isotope effects === Isotopes differ by number of neutrons, which directly impacts physical properties based on mass and size. Normal hydrogen (protium, 1H) has no neutron. Deuterium (2H) has one neutron, and tritium (3H) has two. Neutrons add mass to the atom, leading to different chemical physical properties. This effect is especially strong for hydrogen isotopes, since the added neutron doubles the mass from 1H to 2H. For heavier elements like carbon, nitrogen, oxygen, or sulfur, the mass difference is diluted. Physical chemists often model chemical bonding with the quantum harmonic oscillator (QHO), simplifying a hydrogen-hydrogen bond as two balls connected by a spring. The QHO is based on Hooke's law and is a good approximation of the Morse potential that accurately describes bonding. Modeling H/2H in a chemical reaction demonstrates the energy distributions of isotopes in products and reactants. Lower energy levels for the heavier isotope 2H can be explained mathematically by the QHO's dependence on the inverse of the reduced mass μ. Thus, a larger reduced mass is a larger denominator and thus a smaller zero point energy and a lower energy state in the quantum well.
There are two general classes of glutamate transporters, those that are dependent on an electrochemical gradient of sodium ions (the EAATs) and those that are not (VGLUTs and xCT). The cystine-glutamate antiporter (xCT) is localised to the plasma membrane of cells whilst vesicular glutamate transporters (VGLUTs) are found in the membrane of glutamate-containing synaptic vesicles. Na+-dependent EAATs are also dependent on transmembrane K+ and H+concentration gradients, and so are also known as 'sodium and potassium coupled glutamate transporters'. Na+-dependent transporters have also been called 'high-affinity glutamate transporters', though their glutamate affinity actually varies widely. EAATs are antiporters which carry one molecule of glutamate in along with three Na+ and one H+, while export one K+. EAATs are transmembrane integral proteins which traverse the plasmalemma 8 times. Mitochondria also possess mechanisms for taking up glutamate that are quite distinct from membrane glutamate transporters.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.